Merck KGaA

Merck KGaA secures 16 MW of renewable power in South Korea with a 20‑year PPA to hit 80 % renewable electricity by 2030, cutting CO₂ and boosting investor confidence.

Merck KGaA is poised for growth as it advances its antibody-drug conjugate (ADC) therapy into late-stage trials, while also executing a cost-cutting strategy through the closure of its Ireland API facility, positioning the company for long-term succ…

Merck KGaA has entered into two pricing-related agreements with the US government to maintain its market share and avoid tariff exposure, while also positioning itself for future growth through investments in next-generation fertility therapies and …

Merck KGaA’s stock price surged over 10% in a single trading session, driven by a combination of regulatory developments, market trends, and the company’s own operational outlook, including revised revenue forecasts and promising late-stage clinical…

Merck KGaA, a diversified global healthcare company, is well-positioned to navigate the complex landscape of clinical microbiology, with a robust portfolio and strong financial health, despite facing operational challenges and evolving reimbursement…

Merck KGaA’s recent 2.56% share price decline is a symptom of broader market corrections, but the company’s diversified pipeline, strategic positioning in high-growth markets, and disciplined capital management position it well for long-term growth …

Merck KGaA’s stock price has experienced fluctuations over the past few weeks, influenced by market trends, while the company continues to prioritize research and development in key areas.

Merck KGaA has made significant strides in the pharmaceutical industry with the EU approval of its cancer treatment Ogsiveo, as well as several major partnerships and investments, despite a recent stock rating downgrade.

Merck KGaA has expanded its presence in the US market, solidifying its position as a leader in the industry with its innovative products and advanced peptide synthesis instruments.

Merck KGaA has announced positive phase 3 results for its cancer treatment pimicotinib and plans to acquire SpringWorks Therapeutics Inc. with a $4 billion bond sale.